Untitled design (9).png

Research Involvement

From sponsor-initiated clinical trials to observational cohort studies and investigator-initiated research programs, VIDC makes strides in scientific advancement while providing access to treatment for marginalized and vulnerable populations. 

The overall mission of the VIDC clinical research team is to understand and advance the knowledge of HCV and HIV transmission, infection, prevention and re-infection to recognize how these impact population-level demographics and prevalence. Our research team presents their findings regularly at forums and conferences both nationally and internationally.

The team obtains funding through grants to support community initiatives such as community pop-up clinics, HIV sexual health promotion workshops and weekly patient  support groups. 

Find a list of published papers and conference posters here > 

Copy of Bridging the gap between excelle

Below is a list of observational studies and clinical trials VIDC is currently enrolling in.

If you would like to participate, please reach out to us at info@vidc.ca

Clinical Trials

CAPELLA (GS-US-200-4625)


This study is a randomized, quadruple masked, interventional study. The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen (functional monotherapy) in people living with HIV (PLWH) with multi-drug resistance (MDR). More information >




DOR/ISL (MK-8591A-019)


This is a 2-part, phase 3 clinical study evaluating the antiretroviral activity and safety/tolerability of islatravir (ISL), doravirine (DOR), and a fixed dose combination (FDC) of DOR/ISL (also known as MK-8591A) in heavily treatment-experienced (HTE) participants with human immunodeficiency virus type 1 (HIV-1) infection. It is hypothesized that the percentage of participants receiving DOR/ISL to achieve ≥0.5 log10 decrease in HIV-1 ribonucleic acid (RNA) from study baseline (Day 1) to Day 8 is superior to placebo, each given in combination with failing antiretroviral therapy (ART). More information >





Observational Studies

CAPELLA (GS-US-200-4625)


This study is a randomized, quadruple masked, interventional study. The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen (functional monotherapy) in people living with HIV (PLWH) with multi-drug resistance (MDR). More information >




DOR/ISL (MK-8591A-019)


This is a 2-part, phase 3 clinical study evaluating the antiretroviral activity and safety/tolerability of islatravir (ISL), doravirine (DOR), and a fixed dose combination (FDC) of DOR/ISL (also known as MK-8591A) in heavily treatment-experienced (HTE) participants with human immunodeficiency virus type 1 (HIV-1) infection. It is hypothesized that the percentage of participants receiving DOR/ISL to achieve ≥0.5 log10 decrease in HIV-1 ribonucleic acid (RNA) from study baseline (Day 1) to Day 8 is superior to placebo, each given in combination with failing antiretroviral therapy (ART). More information >





© 2020 by Vancouver Infectious Diseases Centre. 

logo%20png_edited.png